#United States #New York #Class Action #Pomerantz LLP #Applied Therapeutics

Pomerantz Law Firm's Class Action Against Applied Therapeutics

Introduction
Pomerantz LLC has recently filed a class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT), bringing significant attention to alleged securities fraud and unlawful practices attributed to the company’s management. Shareholders who have suffered losses on their investments are especially urged to be aware of upcoming deadlines related to the suit and the potential for seeking recovery of their losses.

Background on the Class Action
The class action lawsuit is rooted in allegations that Applied Therapeutics and some of its key executives engaged in practices that misled shareholders. As part of its actions, the firm is reaching out to affected investors to join the lawsuit. Any individuals who invested in Applied Therapeutics during the specified class period can express interest and potentially be appointed as lead plaintiffs.
Those interested are directed to contact Danielle Peyton at Pomerantz via email or phone. It is vital for prospective class members to include essential information such as their contact details and the number of shares acquired, ensuring their involvement in this significant collective action.

Recent Press Releases from Applied Therapeutics
On November 27, 2024, Applied Therapeutics faced market turbulence following the announcement from the U.S. Food and Drug Administration (FDA) regarding a Complete Response Letter (CRL) for its New Drug Application (NDA) concerning govorestat, a central nervous system-targeting drug. The FDA's correspondence indicated that the NDA could not be approved in its current format due to existing deficiencies within the clinical application, resulting in a notable drop in stock price of 16.06% on that very day.

Further complicating matters, on December 2, 2024, Applied Therapeutics disclosed that it had received a warning letter from the FDA addressing critical issues related to its clinical trials. The letter specifically called out problems with electronic data capture and a dosing error that occurred during the study, which the company claims had been resolved. However, following this disclosure, Applied Therapeutics’ stock dipped an additional 26.29% within a mere three trading sessions.

Prominent Law Firm’s Legacy
Pomerantz LLP is a well-respected firm in the realm of corporate and securities litigation. Founded by the notable Abraham L. Pomerantz, who is acknowledged as one of the early pioneers in class action law, the firm has established a reputation for holding corporations accountable for misconduct and defending the rights of investors. With a history exceeding 85 years of fighting in courts for justice concerning securities fraud and similar claims, Pomerantz continues its commitment to recovering losses inflicted on investors due to corporate wrongdoing.

Conclusion
Investors of Applied Therapeutics are advised to remain vigilant about the details surrounding this class action lawsuit and are encouraged to contact Pomerantz LLP if they meet the criteria. As the deadline of February 18, 2025, approaches, affected shareholders should act promptly to ensure their interests are represented in this important legal endeavor. For more information, potential claimants can visit Pomerantz’s website at www.pomerantzlaw.com.

This situation serves as a timely reminder of the complexities surrounding investments in publicly traded companies and the potential for legal recourse available to shareholders facing unexpected losses.